StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Several other research firms also recently commented on MRNS. JMP Securities dropped their price objective on shares of Marinus Pharmaceuticals from $19.00 to $18.00 and set a market outperform rating for the company in a report on Wednesday, March 8th. HC Wainwright reissued a buy rating and set a $27.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, March 8th. SVB Leerink lowered their price target on shares of Marinus Pharmaceuticals from $27.00 to $23.00 and set an outperform rating for the company in a report on Monday, January 23rd. Cantor Fitzgerald reaffirmed an overweight rating and issued a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, March 8th. Finally, Royal Bank of Canada lowered their price target on shares of Marinus Pharmaceuticals from $23.00 to $22.00 and set an outperform rating for the company in a report on Wednesday, March 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of Moderate Buy and a consensus price target of $27.50.
Marinus Pharmaceuticals Stock Performance
MRNS opened at $6.79 on Thursday. The firm has a 50-day simple moving average of $6.36 and a two-hundred day simple moving average of $5.68. Marinus Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $12.37. The company has a debt-to-equity ratio of 0.90, a current ratio of 10.09 and a quick ratio of 10.09.
Institutional Trading of Marinus Pharmaceuticals
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.